Citius Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview

Citius Pharmaceuticals

08/08/2025 13:38

Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Cranford New Jersey-based  company is expected to report revenue of $4.319 million, according to the mean estimate from 2 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Citius Pharmaceuticals Inc is for a loss of 59 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $5.00, about 74.2% above its last closing price of $1.29

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.03
-0.38
-1.27
Missed
-231.3
Dec. 31 2025
-1.38
-0.58
-1.30
Missed
-125.4
Sep. 30 2024
-1.73
-1.50
-1.59
Missed
-6.1‚Äč
Jun. 30 2024
-1.24
-1.25
-1.50
Missed
-20
‚Äč‚ÄčMar. 31 2024
-1.50
-1.50
-1.25
Beat
16.7
Dec. 31 2023
3.25
3.25
-1.50
Missed
-146.2‚Äč
Sep. 30 2023
-0.50
-2.00
Missed
-300
Jun. 30 2023
-1.42
-1.37
-1.50
Missed
-9.1

This summary was machine generated August 8 at 12:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)